Physician and Media Personality Dr. Drew and Aditxt CEO to Reveal and Discuss Their Personal AditxtScore™ for COVID-19 Resu...
November 30 2020 - 8:30AM
via NewMediaWire – Aditx Therapeutics, Inc. (Aditxt) (the
“Company”) (Nasdaq: ADTX), a life sciences company developing
biotechnologies specifically focused on improving the health of the
immune system through immune monitoring and reprogramming, today
announced that physician and media personality Dr. Drew Pinsky, a
senior advisor to Aditxt, and Aditxt CEO Amro Albanna, will review
the data generated from each of their AdixtScore™ for COVID-19
results. The results will become part of Aditxt’s on-going clinical
study that measures the level and durability of immunity against
COVID-19.
The AditxtEngage™ event will be held on Tuesday, December 1,
2020 at 10:00 am ET. The event will be streamed live from the
AditxtScore™ Center in Richmond, VA, and will include Q&A from
the audience. The event can be accessed by following the
registration link below or through Dr. Drew’s website at
www.DrDrew.com/live.
To register, please go
to: https://us02web.zoom.us/webinar/register/WN_UsDB8qtUTkm1JUZvFZ5A9Q
About Aditx Therapeutics
Aditxt is developing technologies specifically focused on
improving the health of the immune system through immune monitoring
and reprogramming. The immune monitoring technology is designed to
provide a personalized comprehensive profile of the immune system.
The immune reprogramming technology is currently at the
pre-clinical stage and is designed to retrain the immune system to
induce tolerance with an objective of addressing rejection of
transplanted organs, autoimmune diseases, and allergies. For more
information, please visit: www.aditxt.com
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements” within the meaning of the federal
securities laws. Forward-looking statements include statements
regarding the Company’s intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things,
the Company’s ongoing and planned product development; the
Company’s intellectual property position; the Company’s ability to
develop commercial functions; expectations regarding product launch
and revenue; the Company’s results of operations, cash needs,
spending, financial condition, liquidity, prospects, growth and
strategies; the industry in which the Company operates; and the
trends that may affect the industry or the Company. Forward-looking
statements are not guarantees of future performance and actual
results may differ materially from those indicated by these
forward-looking statements as a result of various important
factors, as well as those risks more fully discussed in the section
entitled “Risk Factors” in the Company’s prospectus, dated
September 1, 2020, that was filed with the Securities and Exchange
Commission under File No. 333-248491, as well as discussions of
potential risks, uncertainties, and other important factors in the
Company’s subsequent filings with the Securities and Exchange
Commission. All such statements speak only as of the date made, and
the Company undertakes no obligation to update or revise publicly
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations:
PCG AdvisoryJeff RamsonChief Executive OfficerIR@aditxt.com
646-762-4518www.aditxt.com
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From May 2024 to Jun 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jun 2023 to Jun 2024